STCube

STCube Equity Growth

The Year-over-Year Equity Growth of STCube (052020.KQ) as of Oct 24, 2026 is -23.50 %. In the previous year, Year-over-Year Equity Growth was 167.01 % — a change of -114.07% (lower).

Equity Growth

-23.50 %

YoY

-114.07%

Last updated:

Year-over-Year Equity Growth of STCube is 2025 -23.50 % . Year-over-Year Equity Growth of STCube was 2024 167.01 % . It decreases by -114.07% lower compared to the previous year.

The STCube Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
102.40 KRW
Jan 1, 2019
-25.54 KRW
Jan 1, 2020
25.02 KRW
Jan 1, 2021
-55.13 KRW
Jan 1, 2022
216.87 KRW
Jan 1, 2023
-31.07 KRW
Jan 1, 2024
167.01 KRW
Jan 1, 2025
-23.50 KRW
The STCube Equity Growth history
YEAREquity GrowthYoY
-23.50 %-114.07%
167.01 %-637.61%
-31.07 %-114.32%
216.87 %-493.37%
-55.13 %-320.33%
25.02 %-197.95%
-25.54 %-124.95%
102.40 %-395.93%
-34.60 %-186.91%
39.82 %-1,656.79%
-2.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Year-over-Year Equity Growth of STCube is -23.50 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth STCube since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's STCube historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — STCube

All Key Metrics — STCube